$Arcturus Therapeutics (ARCT.US)$
Arcturus宣佈自我放大 COVID-19 mRNA 生物-疫苗候選ARCt-154在第3期研究中達到主要效力端點。
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
Arcturus宣佈自我放大 COVID-19 mRNA 生物-疫苗候選ARCt-154在第3期研究中達到主要效力端點。
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
已翻譯
1
$強生 (JNJ.US)$
強生支持的登革熱複合物表現出對抗該病毒及所有已知變異株的潛力,包括在老鼠身上。
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
強生支持的登革熱複合物表現出對抗該病毒及所有已知變異株的潛力,包括在老鼠身上。
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
已翻譯
$Arcturus Therapeutics (ARCT.US)$Arcturus宣布獲批准臨床試驗申請,以推進針對SARS-CoV-2 Delta變體和其他引起關注的變體的下一代STARR™ mRNA生物-疫苗ARCt-154。
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
已翻譯
1
3
$Vir Biotechnology (VIR.US)$sotrovimab取得了一些初步積極的結果。
"COMEt-ICE試驗中所有1,057名患者的主要有效性分析顯示,在Day 29與安慰劑相比,因各種原因導致住院超過24小時或死亡的風險減少了79%(調整後相對風險降低)(p<0.001),達到了試驗的主要終點。"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSk-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMEt-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
"COMEt-ICE試驗中所有1,057名患者的主要有效性分析顯示,在Day 29與安慰劑相比,因各種原因導致住院超過24小時或死亡的風險減少了79%(調整後相對風險降低)(p<0.001),達到了試驗的主要終點。"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSk-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMEt-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
已翻譯
2
$Arcturus Therapeutics (ARCT.US)$2021年6月2日
Primordial Genetics授予Arcturus Therapeutics人类和动物治疗的RNA聚合酶独家许可
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
Primordial Genetics授予Arcturus Therapeutics人类和动物治疗的RNA聚合酶独家许可
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
已翻譯
$富途控股 (FUTU.US)$富途及TIGR兩家公司上個月在財報電話會議中透露,他們正在申請新加坡和美國的牌照,以讓當地客戶能夠交易數字貨幣。
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
已翻譯